Geneva, Switzerland, May 24, 2023 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), informs its shareholders that the 2023 Annual General Meeting will be held on Wednesday June 14, 2023 at 3.00 pm at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-les-Ouates, Geneva, Switzerland.
https://geneuro.ch/data/news/GeNeuro-2023-AGM-Documents-Availability-EN.pdf